REFERENCES

1. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004;94:256-66.

2. Onalan R, Onalan G, Tongue E, Ozdener T, Dogan M, Mollamahmutoglu L.

3. Spiewankiewicz B, Stelmachow J, Sawicki W, Cendrowski K, Kuzlik R. Hysteroscopy in cases of cervical polyps. Eur J Gynaecol Oncol 2003;24:67-69.

4. Km TJ, Kim HS, Park CT, Park IS, Hong SR, Park JS, et al. Clinical evaluation of follow-up methods and results of atypical glan­dular cells of undetermined significance (AGUS) detected on cervicovaginal Pap smears. Gynecol Oncol 1999;73:292-98.

5. Vanni R, Dal Cin P, Marras S, et al. Endometrial polyp: another benign tumor characterized by 12q13-q15 changes. Cancer Genet Cytogenet 1993;68:32-33.

6. Inagaki N, Ung L, Otani T, Wilkinson D, Lopata A. Uterine cavity matrix metalloproteinases and cytokines in patients with leiomyoma, adenomyosis or endometrial polyp. Eur J Obstet Gynecol Reproduct Biol 2003;111:197-203.

7. Nogueira AA, SantAna de Almeida EC, Poli Neto OB, Zambelli Ramalho LN, Rosa e Silva JC, Candido dos Reis FJ. Immunohistochemical expression of p63 in endometrial polyps: evidence that a basal cell immunophenotype is main­tained. Menopause 2006;13:826-30.

8. Jakab A, Ovari L, Juhasz B, Birinyi L, Bacsko G, Toth Z. Detection of feeding artery improves the ultrasound diagnosis of endo­metrial polyps in asymptomatic patients. Eur J Obstet Gynecol ReproductBiol 2005;119:103-107.

9. Haimov-Kochman R, Deri-Hasid R, Hamani Y, Voss E. The nat­ural course of endometrial polyps: could they vanish when left untreated? Fertil Steril 2009;92:828.e11-12.

10. Fabres C, Alam V, Balmaceda J, Zegers- Hochschild F, Mackenna A, Fernandez E.

11. Valle RE. Hysteroscopy for gynecologic diagnosis. Clin Obstet Gynecol 1983;26:253-76.

12. Shokeir TA, Shalan HM, El-Shafei MM. Significance of endomet­rial polyps detected hysteroscopically in eumenorrheic infertile women. J Obstet Gynaecol Res 2004;30:84-89.

13. DeWaay DJ, Syrop CH, Nygaard IE, Davis WA, Van Voorhis BJ. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 2002;100:3-7.

14. Papadia A, Gerbaldo D, Fulcheri E, et al. The risk of premalignant and malignant pathology in endometrial polyps: should every polyp be resected? Minerva Ginecologica 2007;59:117-24.

15. Alcazar JL, Castillo G, Minguez JA, Galan MJ. Endometrial blood flow mapping using transvaginal power Doppler sonography in women with postmenopausal bleeding and thickened endomet­rium. Ultrasound Obstet Gynecol 2003;21:583-88.

16. Goldstein SR, Monteagudo A, Popiolek D, Mayberry P, Timor- Tritsch I. Evaluation of endometrial polyps. Am J Obstet Gynecol 2002;186:669-74.

17. De Kroon C. Power Doppler area in the diagnosis of endometrial cancer. Int J Gynecol Cancer 2010;20:1160-65.

18. Anastasiadis PG, Koutlaki NG, Skaphida PG, Galazios GC, Tsikouras PN, Liberis VA. Endometrial polyps: prevalence, detec­tion, and malignant potential in women with abnormal uterine bleeding. Eur J Gynaecol Oncol 2000;21:180-83.

19. Exalto N, Stappers C, van Raamsdonk LAM, Emanuel MH. Gel instillation sonohysterography: first experience with a new tech­nique. Fertil Steril 2007;87:152-55.

20. O’Connell LP, Fries MH, Zeringue E, Brehm W. Triage of ab­normal postmenopausal bleeding: a comparison of endometrial biopsy and transvaginal sonohysterography versus fractional cur­ettage with hysteroscopy. Am J Obstet Gynecol 1998;178:956-61.

21. Clark TJ, Khan KS, Gupta JK. Current practice for the treatment of benign intrauterine polyps: a national questionnaire survey of consultant gynaecologists in UK.

22. Agostini A, Bretelle F, Cravello L, Maisonneuve AS, Roger V, Blanc B. Acceptance of outpatient flexible hysteroscopy by pre­menopausal and postmenopausal women. J Reproduct Med 2003;48:441-43.

23. Jansen FW, Vredevoogd CV, Van Ulzen K, Hermans J, Trimbos JB, Trimbos-Kemper TCM. Complications of hysteroscopy: a pro­spective, multicenter study. Obstet Gynecol 2000;96:266-70.

24. Moghal N. Diagnostic value of endometrial curettage in abnormal uterine bleeding - a histopathological study. J Pak Med Assoc 1997;47:295-99.

25. Lo KW, Yuen PM. The role of outpatient diagnostic hysteroscopy in identifying anatomic pathology and histopathology in the endometrial cavity. J Am Assoc Gynecol Laparosc 2000;7:381-85.

26. Loffer FD. Hysteroscopy with selective endometrial sampling compared with D&C for abnormal uterine bleeding: the value of a negative hysteroscopic view. Obstet Gynecol 1989;73:16-20.

27. Lee C, Ben-Nagi J, Ofili-Yebovi D, Yazbek J, Davies A, Jurkovic D. A new method of transvaginal ultrasound guided polypectomy: a feasibility study. Ultrasound Obstet Gynecol 2006;27:198-201.

28. Preutthipan S, Herabutya Y. Hysteroscopic polypectomy in 240 premenopausal and postmenopausal women. Fertil Steril 2005;83:705-709.

29. Perez-Medina T, Bajo-Arenas J, Salazar F, et al. Endometrial polyps and their implication in the pregnancy rates of patients undergoing intra-uterine insemination: a prospective, random­ized study. Hum Reprod 2005;20:1632-35.

30. Isikoglu M, Berkkanoglu M, Senturk Z, Coertzee K, Ozgur K. Endometrial polyps smaller than 1.5 cm do not affect ICSI out­come. Reprod Biomed Online 2006;12:199-204.

31. Matalliotakis IM, Kourtis AI, Panidis DK. Adenomyosis. Obstet Gynecol Clin North Am 2003;30:63-82.

32. Togashi K, Ozasa H, Konishi I, et al. Enlarged uterus: differen­tiation between adenomyosis and leiomyoma by MR imaging. Radiology 1989;171:531-34.

33. Togashi K. Adenomyosis.

34. Ota H, Igarashi S, Hatarzawa J, et al. Is adenomyosis an immune disease? Hum Reprod Update 1998;4:360-67.

35. Byun JY, Kim SE, Choi BG, et al. Diffuse and focal adenomyosis: MR imaging findings. Radiographics 1999;19:S161-70.

36. Levy G, Dehaene A, Laurent N, et al. An update on adenomyosis. Diagn Interv Imaging 2013:94:3-25.

37. Valentini AL, Speca S, Gui B, Sogua G, Micco M, Bonomo L. Adenomyosis: from the sign to the diagnosis. Imaging, diagnostic pitfalls and differential diagnosis: a pictorial review. Radiol Med 2011;116:1267-87.

38. Reves MF, Goldstein RB, Jones KD. Communications of adenomyosis with the endometrial cavity: visualization with sa­line contrast sonohysterography. Ultrasound Obstet Gynecol 2010;36:115-19.

39. Lo Monte G, Capobianco G, Piva I, Caserta D, Dessole S, Marci R. Hysterosalpingo contrast sonography (HyCoSy): let’s make the point! Arch Gynecol Obstet 2015;291:19-30.

40. Di Donato N, Seracchioli R. How to evaluate adenomyosis in patients affected by endometriosis? Minim Invasive Surg 2014;2014:507230.

41. Exacoustos C, Brienza L, Giovanni A, et al. Adenomyosis: three di­mensional sonographic findings of the junctional zone and correl­ation with histology. Ultrasound Obstet Gynecol 2011;37:471-79.

42. Bazot M, Cortez A, Darai E, et al Ultrasonography com­pared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod 2001;16:2427-33.

43. Taorel P, Laffargue, Dechaud H. Adenomyosis: what imaging modality in the diagnosis and staging? Gynecol Obstet Fertil 2004;32:976-80.

44. Schweppe KW. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas 2009;65:523-27.

45. He SM, Wei MX, et al. Effect of levonorgestrel-releasing intra­uterine system in the treatment of adenomyosis. Zhonghua Fu Chan Ke Za Zhi 2005;40:536-38.

46. Cho S, Nam A, Kim H, et al.

47. Keckstein J. Hysteroscopy and adenomyosis. Contrib Gynecol Obstet 2000;20:41-50.

48. Farquhar C, Brosens I. Medical and surgical management of adenomyosis. Best Pract Res Clin Obstet Gynecol 2006;20:603-16.

49. Lohle PN, De Vries J, Klazen CA, et al. Uterine artery embol­ization for symptomatic adenomyosis with or without uterine leiomyomas with the use of calibrated trisacryl gelatin micro­spheres: midterm clinical and MR imaging follow up. J Vasc Interv Radiol 2007;18;835-41.

50. Bratby MJ, Walker WJ. Uterine artery embolization for symptom­atic adenomyosis: mid-term results. Eur J Radiol 2009;70:128-32.

51. Kitamura Y, Alison SJ, Jha RC, Spies JB, Flick PA, Ascher SM. MRI of adenomyosis: changes with uterine artery embolization. AJR Am J Roentgenol 2006;186:855-64.

52. Yoon SW, Kim KA, Cha SH, et al. Successful use of magnetic res­onance-guided focused ultrasound surgery to relieve symptoms in a patient with symptomatic focal adenomyosis. Fertil Steril 2008;90:2018.e13-15.

53. Wang W, Wag YX, Tang J. Safety and efficacy of high intensity fo­cused ultrasound ablation therapy for adenomyosis. Acad Radiol 2009;16:1416-23.

54. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188: 100-107.

55. Laughlin SK, Schroeder JC, Baird DD. New directions in the epi­demiology of uterine fibroids. Semin Reprod Med 2010;28:204-17.

56. Schmidt L, Sobotka T, Bentzen JG, Nyboe Andersen A. ESHRE Reproduction and Society Task Force. Demographic and medical consequences of the postponement of parenthood. Hum Reprod Update 2012;18:29-43.

57. Office for National Statistics. Births in England in 2013. Available at: http://www.ons.gov.uk/ons/rel/vsob1/birth-summary-tables-- england-and-wales∕2013∕info-births-2013.html.

58. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the in­cidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997;90:967-73.

59. Okolo S. Incidence, aetiology and epidemiology of uterine fi­broids. Best Pract Res Clin Obstet Gynaecol 2008;22:571-88.

60. Ravina JH, Herbreteau D, Ciraru-Vigneron N, et al. Arterial em­bolisation to treat uterine myomata. Lancet 1995;346:671-72.

61. National Institute for Health and Care Excellence. Uterine artery embolisation for fibroids. Interventional procedures guidance [IPG367]. 2010. Available at: https://www.nice.org.uk/guidance/ ipg367.

62. Stewart EA, Gedroyc WM, Tempany CM, et al. Focused ultra­sound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. Am J Obstet Gynecol 2003;189:48-54.

63. Schlesinger D, Benedict S, Diederich C, Gedroyc W, Klibanov A, Larner J. MR-guided focused ultrasound surgery, present and fu­ture. Med Phys 2013;40:080901.

64. Gizzo S, Saccardi C, Patrelli TS, et al. Magnetic resonance-guided focused ultrasound myomectomy: safety, efficacy, subsequent fertility and quality-of-life improvements, a systematic review. Reprod Sci 2014;21:465-76.

65. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409-20.

66. Donnez J, Donnez O, Matule D, et al. Long-term medical man­agement of uterine fibroids with ulipristal acetate. Fertil Steril 2016;105:165-73.e4.

67. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111:1129-36.

68. Day BD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100-107.

69. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997;90:967-73.

70. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94:435-38.

71. Townsend DE, Sparkes RS, Baluda MC, McClelland G. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis by glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 1970;107:1168-73.

72. Hashimoto K, Azuma C, Kamiura S, et al. Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phosphoglycerokinase gene. Gynecol Obstet Invest 1995;40:204-208.

73. Ozisik YY, Meloni AM, Powell M, Surti U, Sandberg AA. Chromosome 7 biclonality in uterine leiomyoma. Cancer Genet Cytogenet 1993;67:59-64.

74. Sargent MS, Weremowicz S, Rein MS, Morton CC. Translocations in 7q22 define a critical region in uterine leiomyomata. Cancer Genet Cytogenet 1994;77:65-68.

75. Andersen J, Barbieri RL. Abnormal gene expression in uterine leiomyomas. J Soc Gynecol Investig 1995;2:663-72.

76. Okolo SO, Gentry CC, Perrett CW, Maclean AB. Familial preva­lence of uterine fibroids is associated with distinct clinical and molecular features. Hum Reprod 2005;20:2321-24.

77. Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM. Uterine leiomyomas. Racial differences in severity, symp­toms and age at diagnosis. J Reprod Med 1996;41:483-90.

78. Vikhlyaeva EM, Khodzhaeva ZS, Fantschenko ND. Familial predisposition to uterine leiomyomas. Int J Gynaecol Obstet 1995;51:127-31.

79. Luoto R, Kaprio J, Rutanen EM, Taipale P, Perola M, Koskenvuo M. Heritability and risk factors of uterine fibroids—the Finnish Twin Cohort study. Maturitas 2000;37:15-26.

80. Wise LA, Palmer JR, Harlow BL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004;159:113-23.

81. Hammoud AO, Asaad R, Berman J, Treadwell MC, Blackwell S, Diamond MP. Volume change of uterine myomas during pregnancy: do myomas really grow? J Minim Invasive Gynecol 2006;13:386-90.

82. Cooper NP, Okolo S. Fibroids in pregnancy—common but poorly understood. Obstet Gynecol Surv 2005;60:132-38.

83. Huang SC, Yu CH, Huang RT, et al. Intratumoral blood flow in uterine myoma correlated with a lower tumor size and volume, but not correlated with cell proliferation or angiogenesis. Obstet Gynecol 1996;87:1019-24.

84. Forssman L. Blood flow in myomatous uteri as measured by intra­arterial ¹³³Xenon. Acta Obstet Gynecol Scand 1976;55:21-14.

85. Forssman L. Distribution of blood flow in myomatous uteri as measured by locally injected i33χenon. Acta Obstet Gynecol Scand 1976;55:101-104.

86. deSouza NM, Williams AD. Uterine arterial embolization for leiomyomas: perfusion and volume changes at MR imaging and relation to clinical outcome. Radiology 2002;222:367-74.

87. Farrer-Brown G, Beilby JOW, Rowles PM. Microvasculature of the uterus: an injection method of study. Obstet Gynecol 1970;35:21-30.

88. Farrer-Brown G, Beilby JOW, Tarbit MH. The vasculature pat­terns in myomatous uteri. J Obstet Gynaecol Br Comnwlth 1970;77:967-75.

89. Walocha JA, Litwin JA, Miodonski AJ. Vascular system of intra­mural leiomyomata revealed by corrosion casting and scanning electron microscopy. Hum Reprod 2003;18:1088-93.

90. Casey R, Rogers PAW, Vollenhoven BJ. An immuohistochemical analysis of fibroid vasculature. Hum Reprod 2000;15:1469-75.

91. Lee BS, Stewart EA, Sahakian M, et al. Interferon-alpha is a po­tent inhibitor of basic fibroblast growth factor-stimulated cell proliferation in human uterine cells. Am J Reprod Immunol 1998;40:19-25.

92. Strawn EY, Novy MJ, Burry KA, et al. Insulin-like growth factor I promotes leiomyoma cell growth in vitro. Am J Obstet Gynecol 1995;172:1837-44.

93. Swartz CD, Afshari CA, Yu L, et al. Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines. Mol Hum Reprod 2005;11:411-50.

94. Vollenhoven BJ, Herington AC, Healy DL. Messenger ribo­nucleic acid expression of the insulin-like growth factors and their binding proteins in uterine fibroids and myometrium. J Clin Endocrinol Metab 1993;76:1106-10.

95. Gao Z, Matsuo H, Wang Y, et al. Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 2001;86:5593-99.

96. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 2007;87:725-36.

97. Stovall DW. Clinical symptomatology of uterine leiomyomas. Clin Obstet Gynaecol 2001;44:364-71.

98. Christiansen JK. The facts about fibroids. Postgrad Med 1993;9:129-37.

99. Gupta S, Jose J, Manyonda IT. Clinical presentation of fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:615-26.

100. Lacey CG. Benign disorders of the uterine corpus. In: Pernoll ML (ed), Current Obstetric and Gynaecologic Diagnosis and Treatment, 7th edn, pp. 732-38. Norwalk, CN: Appleton & Lange; 1991.

101. Day Baird D, Dunson DB, Hill MC, et al. High cumulative inci­dence of leiomyoma in black and white women: ultrasound evi­dence. Am J Obstet Gynecol 2003;188;100-107.

102. Kjerulff KH, Langenberg P, Seidman JD, et al. Uterine leiomyomas: racial differences in severity, symptoms and age at diagnosis. J Reprod Med 1996;41:483-90.

103. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997;90:967-73.

104. Ozumba BC, Megafu UC, Igwegbe AO. Uterine fibroids: clinical presentation and management in a Nigerian teaching hospital. Ir Med J 1992;85:158-59.

105. Flake GP, Andersen J, Dixon D. Etiology and pathogen­esis of uterine leiomyomas: a review. Environ Health Perspect 2003;111:1037-54.

106. McLucas B. Diagnosis, imaging and anatomical classifica­tion of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:627-42.

107. Hurley V Imaging techniques for fibroid detection. Baillieres Clin Obstet Gynaecol 1998;12:213-24.

108. Freimanis MG, Jones AF. Transvaginal ultrasonography. Radiol Clin North Am 1992;30:955-76.

109. Schiller VL, Grant E. Doppler ultrasonography of the pelvis. Radiol Clin North Am 1992;30:735-42.

110. Sohaey R, Woodward P. Sonohysterography: technique, endo­metrial findings, and clinical applications. Semin Ultrasound CT MR 1999;20:250-58.

111. Dueholm M, Lundorf E, Olesen F. Imaging techniques for evalu­ation of the uterine cavity and endometrium in premenopausal patients before minimally invasive surgery. Obstet Gynecol Surv 2002;57:389-403.

112. Dueholm M, Lundorf E, Hansen E, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 2002;186:409-15.

113. Kugligowska E, Deeds L, Lu K. Pelvic pain: overlooked and underdiagnosed gynecologic conditions. Radiographics 2005;25:3-20.

114. Spies JB, Ascher SA, Roth AR, et al. Uterine artery embolization for leiomyomata. Obstet Gynecol 2001;98:29-34.

115. Ascher SM, Arnold LL, Patt RH, et al. Adenomyosis: prospective comparison of MR imaging and transvaginal sonography. Radiology 1994;190:803-806.

116. Fedele L, Bianchi S, Dorta M, et al. Transvaginal ultrasonography in the differential diagnosis of adenomyoma versus leiomyoma. Am J Obstet Gynecol 1992;167:603-606.

117. Pelage JP, Cazejust J, Pluot E, et al. Uterine fibroid vascular­ization and clinical relevance to uterine fibroid embolization. Radiographics 2005;25:S99-117.

118. Wu JM, Wechter ME, Geller EJ, et al. Hysterectomy rates in the United States, 2003. Obstet Gynecol 2007;110:1091-95.

119. Wright KN, Jonsdottir GM, Jorgensen S, et al. Costs and out­comes of abdominal, vaginal, laparoscopic and robotic hysterec­tomies. JSLS 2012;16:519-24.

120. Thakkar R, Ayers S, Clarkson P, et al. A comparison of out­comes following total or subtotal hysterectomy. N Engl J Med 2002;347:1318-25.

121. Carlson K, Miller B, Fowler F. The Maine women’s health study: outcomes of hysterectomy. Br J Obstet Gynaecol 1994;83:556-65.

122. Talaulikar VS, Gupta S, Manyonda IT. Pregnancy after complex myomectomy: neither age of patient nor size, number or location of fibroids should be a barrier. JRSM Short Rep 2012;3:19.

123. Mukhopadhaya N, De Silva C, Manyonda IT. Conventional myomectomy. Best Pract Res Clin Obstet Gynaecol 2008;22:677-705.

124. Bonney V A clamp forceps for controlling haemorrhage when performing myomectomy. Br J Obstet Gynaecol 1923;30:447-49.

125. Ngeh N, Belli AM, Morgan R, Manyonda IT. Pre-myomectomy uterine artery embolization minimizes operative blood loss. Br J Obstet Gynaecol 2004;111:1139-40.

126. Taylor A, Sharma M, Tsirkas P, et al. Reducing blood loss at open myomectomy using triple tourniquets: a randomized controlled trial. Br J Obstet Gynaecol 2005;112:340-45.

127. Tsuji S, Takahashi K, Yomo H, et al. Effectiveness of anti-adhe­sion barriers in preventing adhesions after myomectomy in pa­tients with uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol 2005;123:244-48.

128. Agdi M, Tulandi T. Endoscopic management of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:707-16.

129. Rosetti A, Sizzi O, Soranna L, et al. Long-term results of laparo­scopic myomectomy: recurrence rates in comparison with ab­dominal myomectomy. Hum Reprod 2001;16:770-74.

130. Loffer FD. Improving the results of hysteroscopic submucosal myomectomy for menorrhagia by concomitant endometrial ab­lation. J Minim Invasive Gynecol 2005;12:254-60.

131. Emmanuel MH, Wamsteker K, Hart AA, et al. Long-term results of hysteroscopic myomectomy for abnormal uterine bleeding. Obstet Gynecol 1999;93:743-48.

132. Ravina JH, Herbreteau D, Ciraru-Vigneron N, et al. Arterial em­bolisation to treat uterine myomata. Lancet 1995;346:671-72.

133. Bratby MJ, Belli A-M. Radiological treatment of symptomatic fi­broids. Best Pract Res Clin Obstet Gynaecol 2008;22:717-34.

134. Chua GC, Wilsher M, Young MP, Manyonda I, Morgan R, Belli AM. Comparison of particle penetration with non-spherical polyvinyl alcohol versus trisacryl gelatin microspheres in women undergoing premyomectomy uterine artery embolization. Clin Radiol 2005;60:116-22.

135. Pelage JP, Guaou NG, Jha RC, Ascher SM, Spies JB. Uterine fi­broid tumors: long-term MR imaging outcome after emboliza­tion. Radiology 2004;230:803-809.

136. Spies JB, Allison S, Flick P, et al. Spherical polyvinyl alcohol versus tris-acryl gelatin microspheres for uterine artery embol­ization for leiomyomas: results of a limited randomized com­parative study. J Vasc Interv Radiol 2005;16:1431-37.

137. Marret H, Alonso AM, Cottier JP, Tranquart F, Herbreteau D, Body G. Leiomyoma recurrence after uterine artery emboliza­tion. J Vasc Interv Radiol 2003;14:1395-99.

138. Nicholson T. Outcome in patients undergoing unilateral uterine artery embolization for symptomatic fibroids. Clin Radiol 2004;59:186-91.

139. Volkers NA, Hehenkamp WJ, Birnie E, Ankum WM, Reekers JA. Uterine artery embolization versus hysterectomy in the treat­ment of symptomatic uterine fibroids: 2 years’ outcome from the randomized EMMY trial. Am J Obstet Gynecol 2007;196:519. e1-11.

140. Hehenkamp WJ, Volkers NA, Donderwinkel PF, et al. Uterine ar­tery embolization versus hysterectomy in the treatment of symp­tomatic uterine fibroids (EMMY trial): peri- and postprocedural results from a randomized controlled trial. Am J Obstet Gynecol 2005;193:1618-29.

141. Hehenkamp WJ, Volkers NA, Birnie E, Reekers JA, Ankum WM. Pain and return to daily activities after uterine artery emboliza­tion and hysterectomy in the treatment of symptomatic uterine fibroids: results from the randomized EMMY trial. Cardiovasc Intervent Radiol 2006;29:179-87.

142. Edwards RD, Moss JG, Lumsden MA, et al. Uterine-artery em­bolization versus surgery for symptomatic uterine fibroids. N Engl J Med 2007;356:360-70.

143. National Institute for Health and Care Excellence: Uterine ar­tery embolisation for fibroids. Interventional procedures guid­ance [IPG367]. Available at: https://www.nice.org.uk/guidance/ ipg367.

144. Manyonda IT, Bratby M, Horst JS, et al. Uterine artery embolization versus myomectomy: impact on quality of life­results of the FUME (Fibroids of the Uterus: myomectomy versus Embolization) Trial. Cardiovasc Intervent Radiol. 2012;35:530-36

145. Fruehauf JH, Back W, Eiermann A, et al. High-intensity focused ultrasound for the targeted destruction of uterine tissues: experi­ences from a pilot study using a mobile HIFU unit. Arch Gynecol Obstet 2008;277:143-50.

146. Leslie TA, Kennedy JE. High intensity focused ultrasound in the treatment of abdominal and gynaecological diseases. Int J Hyperthermia 2007;23:173-82.

147. Funaki K, Fukunishi H, Funaki T, Sawada K, Kaji Y, Maruo T. Magnetic resonance-guided focused ultrasound surgery for uterine fibroids: relationship between the therapeutic effects and signal intensity of preexisting T2-weighted magnetic resonance images. Am J Obstet Gynecol 2007;196:184.e1-6.

148. Gedroyc WM, Anstee A. MR-guided focused ultrasound. Expert RevMedDevices 2007;4:539-47.

149. Rabinovici J, Inbar Y, Revel A, et al. Clinical improvement and shrinkage of uterine fibroids after thermal ablation by magnetic resonance- guided focused ultrasound surgery. Ultrasound Obstet Gynecol 2007;30:771-77.

150. Hindley JT, Law PA, Hickey M, et al. Clinical outcomes following percutaneous magnetic resonance image guided laser ablation of symptomatic uterine fibroids. Hum Reprod 2002;17:2737-41.

151. Manyonda IT, Gorti M. Costing magnetic resonance-guided fo­cused ultrasound surgery, a new treatment for symptomatic fi­broids. BJOG 2008;115:551-53.

152. Wilson EA, Yang F, Rees ED. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissue. Obstet Gynecol 1980;55:20-24.

153. Tamaya T, Fujimoto J, Okada H. Comparison of cellular levels of steroid receptors in uterine leiomyomas and myometrium. Acta Gynaecol Scand 1985;64:307-309.

154. Talaulikar VS, Belli A, Manyonda I. GnRH agonists: do they have a place in the modern management of fibroid disease? J Obstet Gynecol India 2012;62:506-10.

155. Dubuisson JB, Fauconnier A, Fourchotte V, Babaki-Fard K, Coste J, Chapron C. Laparoscopic myomectomy: predicting the risk of conversion to an open procedure. Human Reprod 2001;16:1726-31.

156. Campo S, Garcea N. Laparoscopic myomectomy in premeno­pausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues. Human Reprod 1999;14:1:44-48

157. Vercellini P, Maddalena S, Giorgi OD, Aimi G, Crosignani PG. Abdominal myomectomy for infertility: a comprehensive review. Human Reprod 1998;13:873-79.

158. Fauconnier A, Chapron C, Babaki-Fard K, Dubuisson JB. Recurrence of leiomyomata after myomectomy. Hum Reprod Update 2000;6:595-602.

159. Lethaby A, Vollenhoven B. Fibroids (uterine moyamtosis, leiomyomas). Clin Evid 2002;7:1666-78.

160. Ohara N, Xu Q, Matsuo H, Maruo T Progesterone and pro­gesterone receptor modulator in uterine leiomyoma growth. In: Maruo T, Mardon H, Stewart C (eds), Translational Research in Uterine Biology. Amsterdam: Elsevier; 2008.

161. Ohara N, Morikawa A, Chen W, et al. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod Sci 2007;14 Suppl 8:20-27.

162. Xu Q, Ohara N, Liu J, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase in­ducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008;14:181-91.

163. Yoshida S, Ohara N, Xu Q, et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 2010;28:260-73.

164. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409-20.

165. Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421-32.

166. Donnez J, Donnez O, Matule D, et al. Long-term medical man­agement of uterine fibroids with ulipristal acetate. Fertil Steril 2016;105:165-73.e4.

167. Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015;103:519-27.e3.

168. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009;21:318-24.

169. Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update 2007;13:567-80.

170. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modu­lators. Mod Pathol 2008;21:591-98.